Variation in the fibroblast growth factor 23 (FGF23) gene associates with serum FGF23 and bone strength in infants

被引:1
|
作者
Enlund-Cerullo, Maria [1 ,2 ,3 ,4 ]
Holmlund-Suila, Elisa [1 ,2 ,4 ]
Valkama, Saara [1 ,2 ,4 ]
Hauta-alus, Helena [1 ,2 ,4 ,5 ,6 ,7 ]
Rosendahl, Jenni [1 ,2 ,4 ]
Andersson, Sture [1 ,2 ]
Pekkinen, Minna [1 ,2 ,3 ,4 ]
Makitie, Outi [1 ,2 ,3 ,4 ,8 ,9 ]
机构
[1] Univ Helsinki, Childrens Hosp, Pediat Res Ctr, Helsinki, Finland
[2] Helsinki Univ Hosp, Childrens Hosp, Pediat Res Ctr, Helsinki, Finland
[3] Folkhalsan Inst Genet, Folkhalsan Res Ctr, Helsinki, Finland
[4] Univ Helsinki, Fac Med, Res Program Clin & Mol Metab, Helsinki, Finland
[5] Natl Inst Hlth & Welf THL, Publ Hlth Res, Helsinki, Finland
[6] Oulu Univ Hosp, PEDEGO Res Unit, MRC Oulu, Oulu, Finland
[7] Univ Oulu, PEDEGO Res Unit, MRC Oulu, Oulu, Finland
[8] Karolinska Univ Hosp, Dept Mol Med & Surg, Stockholm, Sweden
[9] Karolinska Univ Hosp, Karolinska Inst, Ctr Mol Med, Clin Genet, Stockholm, Sweden
基金
瑞典研究理事会; 芬兰科学院;
关键词
FGF23; genetic variation; vitamin D; bone strength; infants (0-24 months); DOMINANT HYPOPHOSPHATEMIC RICKETS; PHYSIOLOGICAL-ROLE; MINERAL DENSITY; VITAMIN-D; PHOSPHATE; MUTATIONS; CHILDREN;
D O I
10.3389/fgene.2023.1192368
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Introduction: The effects of genetic variation in fibroblast growth factor 23 (FGF23) are unclear. This study explores the associations of single-nucleotide polymorphisms (SNPs) of FGF23 with phosphate and vitamin D metabolism and bone strength in early childhood. Methods: The study is part of the vitamin D intervention in infant (VIDI) trial (2013-2016), in which healthy term infants born to mothers of Northern European origin received vitamin D-3 supplementation of 10 or 30 mu g/day from 2 weeks to 24 months of age (ClinicalTrials.gov NCT01723852). Intact and C-terminal FGF23 (cFGF23), 25-hydroxyvitamin D (25-OHD), parathyroid hormone, phosphate, and peripheral quantitative computed tomography (pQCT)-derived bone strength parameters were analyzed at 12 and 24 months. The study included 622 VIDI participants with genotyping data on FGF23 SNPs rs7955866, rs11063112, and rs13312770. Results: Rs7955866 minor allele homozygotes had lowest cFGF23 at both time-points (mixed model for repeated measurements, p(variant) = 0.009). Minor alleles of rs11063112 were associated with a greater age-related decrease in phosphate concentration (p(interaction) = 0.038) from 12 to 24 months. Heterozygotes of rs13312770 had the greatest total bone mineral content (total BMC), cross-sectional area (total CSA), and polar moment of inertia (PMI) at 24 months (ANOVA p = 0.005, 0.037, and 0.036, respectively). Rs13312770 minor alleles were associated with a greater increase of total BMC, but a smaller increase of total CSA and PMI, during follow-up (p(interaction) <0.001, 0.043, and 0.012, respectively). Genotype of FGF23 did not modify 25-OHD. Conclusion: The study finds that genetic variation in FGF23 modifies cFGF23, phosphate, and pQCT-derived bone strength parameters from 12 to 24 months of age. These findings potentially promote an understanding of the regulation of FGF23 and its role in bone metabolism and temporal changes thereof during early childhood.
引用
收藏
页数:18
相关论文
共 50 条
  • [31] Fibroblast Growth Factor 23 (FGF23) after Pediatric Renal Transplantation (PRT).
    van Husen, Michael
    Fischer, Ann-Katrin
    Klaassen, Ilka
    Lehnhardt, Anja
    Moeller, Kristina
    Mueller-Wiefel, Dirk E.
    Kemper, Markus J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 714 - 714
  • [32] BONE METABOLISM AND FIBROBLAST GROWTH FACTOR 23 (FGF23) AFTER PEDIATRIC RENAL TRANSPLANTATION (PRT)
    van Husen, M.
    Fischer, A. -K.
    Klaassen, I.
    Lehnhardt, A.
    Moeller, K.
    Kemper, M. J.
    TRANSPLANT INTERNATIONAL, 2010, 23 : 33 - 33
  • [33] Levels of Circulating Fibroblast Growth Factor 23 (FGF23) and Prognosis in Cancer Patients with Bone Metastases
    Mansinho, Andre
    Ferreira, Arlindo R.
    Casimiro, Sandra
    Alho, Irina
    Vendrell, Ines
    Costa, Ana Lucia
    Sousa, Rita
    Abreu, Catarina
    Pulido, Catarina
    Macedo, Daniela
    Pacheco, Teresa R.
    Correia, Lurdes
    Costa, Luis
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (03):
  • [34] Fibroblast Growth Factor 23 (FGF23) in Pediatric chronic Kidney disease (CKD)
    van Husen, M.
    Fischer, A. K.
    Klaassen, I.
    Lehnhardt, A. L.
    Moeller, K.
    Mueller-Wiefel, D. E.
    Kemper, M. J.
    PEDIATRIC NEPHROLOGY, 2009, 24 (04) : 899 - 900
  • [35] FGF23 GENE POLYMORPHISM AND SERUM FGF23 IN KAWASAKI DISEASE (KD): POSSIBLE PREDICTORS OF SUBCLINICAL ATHEROSCLEROSIS
    Masi, L.
    Falcini, F.
    Franceschelli, F.
    Leoncini, G.
    Amedei, A.
    Falchetti, A.
    Cavalli, L.
    Capannini, S.
    Tanini, A.
    Brandi, M. L.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 : 118 - 118
  • [36] HYPOPHOSPHATAEMIA AND FGF23
    Fukumoto, S.
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 : S514 - S514
  • [37] FGF23 and Klotho
    Kuro-o, Makoto
    ENDOCRINE JOURNAL, 2010, 57 : S243 - S243
  • [38] FGF23 AND THE PARATHYROID
    Silver, Justin
    Naveh-Many, Tally
    ENDOCRINE FGFS AND KLOTHOS, 2012, 728 : 92 - 99
  • [39] Regulation of FGF23: Beyond Bone
    Petra Simic
    Jodie L Babitt
    Current Osteoporosis Reports, 2021, 19 : 563 - 573
  • [40] Regulation of FGF23: Beyond Bone
    Simic, Petra
    Babitt, Jodie L.
    CURRENT OSTEOPOROSIS REPORTS, 2021, 19 (06) : 563 - 573